These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16102117)

  • 21. Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia.
    John TE; Hallisey RK
    Pharmacotherapy; 2005 Oct; 25(10):1383-8. PubMed ID: 16185183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics study of recombinant hirudin in the plasma of rats using chromogenic substrate, ELISA, and radioisotope assays.
    Jiang SY; Jiao J; Zhang TT; Xu YP
    PLoS One; 2013; 8(6):e64336. PubMed ID: 23785400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study.
    Scalambrino E; Padovan L; Chantarangkul V; Clerici M; Artoni A; Peyvandi F; Tripodi A
    Int J Lab Hematol; 2020 Jun; 42(3):e128-e131. PubMed ID: 32086868
    [No Abstract]   [Full Text] [Related]  

  • 24. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].
    Kher A; Gouin I; Samama MM
    Ann Biol Clin (Paris); 2000; 58(5):575-9. PubMed ID: 11022100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.
    Demir M; Iqbal O; Untch B; Hoppensteadt DA; Gaikwad BS; Fareed J
    Clin Appl Thromb Hemost; 2001 Jan; 7(1):38-43. PubMed ID: 11190903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity.
    Vogel GM; Meuleman DG; Van Dinther TG; Buijsman R; Princen AW; Smit MJ
    J Thromb Haemost; 2003 Sep; 1(9):1945-54. PubMed ID: 12941035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombosis prophylaxis in critically ill patients.
    Fries D
    Wien Med Wochenschr; 2011 Feb; 161(3-4):68-72. PubMed ID: 21404142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Facts and artefacts of coagulation assays for factor Xa inhibitors.
    Haas S
    Thromb Haemost; 2010 Apr; 103(4):686-8. PubMed ID: 20174751
    [No Abstract]   [Full Text] [Related]  

  • 30. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin.
    Hantgan RR; Jerome WG; Hursting MJ
    Blood; 1998 Sep; 92(6):2064-74. PubMed ID: 9731064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting the pharmacology of thrombin inhibitors.
    Adams TE; Everse SJ; Mann KG
    J Thromb Haemost; 2003 May; 1(5):1024-7. PubMed ID: 12871372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Garcia DA; Baglin TP; Weitz JI; Samama MM
    Chest; 2012 Feb; 141(2 Suppl):e24S-e43S. PubMed ID: 22315264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
    J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
    Van Cott EM; Roberts AJ; Dager WE
    Semin Thromb Hemost; 2017 Apr; 43(3):270-276. PubMed ID: 28052306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Argatroban for off-pump coronary artery bypass surgery.
    Nielsen VG
    Anesth Analg; 2003 Oct; 97(4):1201-1202. PubMed ID: 14500190
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban.
    Harenberg J; Jörg I; Fenyvesi T; Piazolo L
    J Thromb Thrombolysis; 2005 Feb; 19(1):65-9. PubMed ID: 15976970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant hirudin as anticoagulant during cardiopulmonary bypass.
    Riess FC; Kormann J; Poetzsch B
    Anesthesiology; 2000 Dec; 93(6):1551-2. PubMed ID: 11149460
    [No Abstract]   [Full Text] [Related]  

  • 38. A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.
    Curzio KM; Cheng-Lai A; Kheyfets V; Sinnet M; Billett HH
    J Thromb Thrombolysis; 2009 Aug; 28(2):117-23. PubMed ID: 18827975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery.
    Choi TS; Khan AI; Greilich PE; Kroll MH
    Am J Clin Pathol; 2006 Feb; 125(2):290-5. PubMed ID: 16393689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.